BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 27466555)

  • 1. The Diagnostic and Prognostic Value of sIL-2R as an Immune Biomarker in Head and Neck Cancers.
    Gross M; Meirovich A; Rachmut J; Kalichman I; Peretz T; Eliashar R; Barak V
    Anticancer Res; 2016 Aug; 36(8):4347-52. PubMed ID: 27466555
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Diagnostic and Prognostic Value of Tumor Markers (CEA, SCC, CYFRA 21-1, TPS) in Head and Neck Cancer Patients.
    Barak V; Meirovitz A; Leibovici V; Rachmut J; Peretz T; Eliashar R; Gross M
    Anticancer Res; 2015 Oct; 35(10):5519-24. PubMed ID: 26408719
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The soluble interleukin-2 receptor--a marker for squamous cell carcinoma of the upper aerodigestive tract.
    Gottschlich S; Görögh T; Lippert BM; Niemann AM; Folz BJ; Werner JA
    Anticancer Res; 1997; 17(4B):2921-2. PubMed ID: 9329564
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The clinical significance of serum soluble interleukin 2 receptor (sIL-2R) concentration in lung cancer.
    Naumnik W; Chyczewska E
    Folia Histochem Cytobiol; 2001; 39 Suppl 2():185-6. PubMed ID: 11820599
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The dynamic study of cytokines pre- and postoperation in patients with carcinoma of larynx].
    Wang Q; Feng Y; Zhang X; Wang H; Xu D
    Lin Chuang Er Bi Yan Hou Ke Za Zhi; 2001 Jun; 15(6):255-7. PubMed ID: 12541774
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Diagnostic and prognostic significance of serum soluble interleukin 2 receptor in children with malignancies].
    Bień E; Balcerska A; Ciesielski D
    Wiad Lek; 2006; 59(1-2):10-5. PubMed ID: 16646285
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum levels of interleukin-18 (IL-18) and soluble interleukin-2 receptor (sIL-2R) in lung cancer.
    Naumnik W; Chyczewska E; Kovalchuk O; Tałałaj J; Izycki T; Panek B
    Rocz Akad Med Bialymst; 2004; 49():246-51. PubMed ID: 15631351
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum soluble interleukin-2 receptor concentrations as an independent prognostic marker in head and neck cancer.
    Tartour E; Mosseri V; Jouffroy T; Deneux L; Jaulerry C; Brunin F; Fridman WH; Rodriguez J
    Lancet; 2001 Apr; 357(9264):1263-4. PubMed ID: 11418153
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High Level of Serum Soluble Interleukin-2 Receptor Is Associated With Poor Survival in Patients With First Relapsed or Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified: A Retrospective Study.
    Morita-Fujita M; Katoh D; Shimomura Y; Ishikawa T
    Clin Lymphoma Myeloma Leuk; 2019 Jul; 19(7):e337-e342. PubMed ID: 31053551
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum level of a soluble receptor for interleukin-2 as a prognostic factor in patients with gastric cancer.
    Saito H; Tsujitani S; Ikeguchi M; Maeta M; Kaibara N
    Oncology; 1999 Apr; 56(3):253-8. PubMed ID: 10202282
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum-soluble interleukin-2 receptor (sIL-2R) level determines clinical outcome in patients with aggressive non-Hodgkin's lymphoma: in combination with the International Prognostic Index.
    Goto H; Tsurumi H; Takemura M; Ino-Shimomura Y; Kasahara S; Sawada M; Yamada T; Hara T; Fukuno K; Goto N; Okuno M; Takami T; Seishima M; Moriwaki H
    J Cancer Res Clin Oncol; 2005 Feb; 131(2):73-9. PubMed ID: 15503137
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Soluble interleukin-2 receptor alpha is elevated in sera of patients with benign ovarian neoplasms and epithelial ovarian cancer.
    Hurteau JA; Woolas RP; Jacobs IJ; Oram DC; Kurman CC; Rubin LA; Nelson DL; Berchuck A; Bast RC; Mills GB
    Cancer; 1995 Nov; 76(9):1615-20. PubMed ID: 8635066
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Relation between the expression of sIL-2R and the relapse in patients with acute lymphoblastic leukemia].
    Liu J; Wu DS; Zhang S; Yan CH; Zhou Y; Zhang YD; Qi ZH
    Beijing Da Xue Xue Bao Yi Xue Ban; 2005 Jun; 37(3):249-51. PubMed ID: 15968312
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IL-10 and sIL-2R serum levels as possible peripheral blood prognostic markers in the passage from adenoma to colorectal cancer.
    Berghella AM; Pellegrini P; Del Beato T; Adorno D; Casciani CU
    Cancer Biother Radiopharm; 1997 Aug; 12(4):265-72. PubMed ID: 10851474
    [TBL] [Abstract][Full Text] [Related]  

  • 15. sIL-2R- an Immuno-biomarker for Prediction of Metastases in Uveal Melanoma.
    Barak V; Kalickman I; Pe'er J
    Anticancer Res; 2022 Mar; 42(3):1447-1453. PubMed ID: 35220238
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Serum soluble interleukin-2 receptor levels in patients with renal cell carcinoma: a comparison of values before and after surgery].
    Tsukamoto S; Ishikawa S; Yamauchi A; Saitou S
    Hinyokika Kiyo; 2000 Oct; 46(10):695-9. PubMed ID: 11215193
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of serum soluble interleukin-2 receptor levels to monitor the progression of cutaneous T-cell lymphoma.
    Vonderheid EC; Zhang Q; Lessin SR; Polansky M; Abrams JT; Bigler RD; Wasik MA
    J Am Acad Dermatol; 1998 Feb; 38(2 Pt 1):207-20. PubMed ID: 9486676
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Soluble interleukin-2 receptor in stage I-III melanoma.
    Ottaiano A; Leonardi E; Simeone E; Ascierto PA; Scala S; Calemma R; Bryce J; Caracò C; Satriano RA; Gianfranco N; Franco R; Botti G; Castello G
    Cytokine; 2006 Feb; 33(3):150-5. PubMed ID: 16517174
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship between serum levels of soluble interleukin-2 receptor and various disease parameters in patients with squamous cell carcinoma of the esophagus.
    Oka M; Hazama S; Takahashi M; Yamamoto K; Abe T; Yoshino S; Hayashi H; Tangoku A
    Hepatogastroenterology; 1999; 46(28):2254-9. PubMed ID: 10521976
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proinflammatory cytokines as serum biomarker in oral carcinoma-A prospective multi-biomarker approach.
    Schiegnitz E; Kämmerer PW; Schön H; Blatt S; Berres M; Sagheb K; Al-Nawas B
    J Oral Pathol Med; 2018 Mar; 47(3):268-274. PubMed ID: 29272054
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.